Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

A vaccine against human immunodeficiency virus (HIV) seems to be on the horizon. Correlates of risk of infection for [corrected] the RV144 vaccine trial have been found. There is understanding of what makes HIV envelope-specific antibodies broadly neutralizing and new T cell vaccine approaches can overcome virus variability.

Original publication

DOI

10.1038/ni.2264

Type

Journal article

Journal

Nat Immunol

Publication Date

18/04/2012

Volume

13

Pages

423 - 427

Keywords

AIDS Vaccines, Animals, Antibodies, Neutralizing, Antibodies, Viral, CD4-Positive T-Lymphocytes, CD8-Positive T-Lymphocytes, Clinical Trials as Topic, HIV Infections, HIV-1, Humans, Immunoglobulin A, Immunoglobulin G, Macaca mulatta, T-Lymphocytes, env Gene Products, Human Immunodeficiency Virus